The FDA approved Ranluspec, an interchangeable biosimilar referencing Lucentis, as a treatment for vision-threatening retinal diseases, according to a press release from Lupin.
June 05, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
The FDA approved Lumvoa, a full insulin-like growth factor 1 receptor antagonist, for the treatment of thyroid eye disease,…
The FDA granted orphan drug designation and fast track designation to Lacripep, according to a press release from TearSolutions.…
Find the latest Presbyopia news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you…
FDA approves Viridian's Lumvoa for thyroid eye disease, launching competition with Amgen's $1.9B Tepezza on efficacy and infusion…
CLEVELAND — For the first time in decades, targeted therapies to treat cutaneous lupus erythematosus are advancing through the…
The FDA granted priority review to a supplemental biologics license application for Enspryng for thyroid eye disease, according…
